Sign in
CompletedNo phase

Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease

Key facts

Who runs it
University of Washington
Where
Seattle, United StatesSee the site
Trial code
Status
Completed
People taking part
78 people enrolled
Started
15 Mar 2023
Ended
25 Jul 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Promoting Resilience in Stress Management (PRISM)
  • Usual Care
Record updated
15 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • adults with moderate or complex ACHD, stages B, C, or D as defined by the 2018 ACHD guidelines
  • receive care in our health system

Who cannot take part

  • diagnosis of another life-limiting illness
  • inability to participate in study activities independently and in English

Where in United States

  • University of WashingtonSeattle, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the feasibility and preliminary efficacy of the Promoting Resilience in Stress Management (PRISM) intervention in patients with adult congenital heart disease.

The 2 groups in the trial

  • PRISM InterventionTreatment being tested

    Subjects in this group will receive the PRISM intervention

    Treatment: Promoting Resilience in Stress Management (PRISM)

  • Usual CarePlacebo, for comparison

    Subjects in this arm will receive usual care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
15 December 2025